Friday, 16 October 2026European Markets

SQLI, NOVABASE,SGPS, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(vianews) - sqli (sqi.pa) is among this list of stock assets with the highest dividend rate and return on equity on the technology sector.

financial asset price forward dividend yield return on equity
sqli (sqi.pa) €41.60 3.04% 7.63%
novabase,sgps (nba.ls) €5.28 2.26% 14.03%
coheris (coh.pa) €4.22 1.46% 21.37%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. sqli (sqi.pa)

3.04% forward dividend yield and 7.63% return on equity

sqli sa engages in digital experience and unified commerce businesses in france and internationally. the company provides e-commerce strategy and acceleration, solution design and technology architecture, product information management, marketplace, digital store, and e-commerce marketing services; web design and development, digital workplace, mobile development, website performance, custom applications and configuration solutions for experience platforms; and technology and transformation solutions, including custom applications, outsourced service centers, multi-technology, enterprise architecture, application management and hosting, and agile and lean. it also offers business intelligence/data visualization, data modernization/move to cloud, mdm/pim, analytics, data science, big data, and unified customer data solutions; digital marketing and design services comprising customer journey and user experience, social media marketing, content and motion design, and design sprint services; and digital consulting services, such as digital strategy and roadmap, audit and scoping, digital responsibility, digital marketing strategy, and experience and change management. sqli sa was incorporated in 1990 and is headquartered in levallois-perret, france.

earnings per share

as for profitability, sqli has a trailing twelve months eps of €1.65.

pe ratio

sqli has a trailing twelve months price to earnings ratio of 25.21. meaning, the purchaser of the share is investing €25.21 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.63%.

volume

today's last reported volume for sqli is 101 which is 66.44% below its average volume of 301.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, sqli's stock is considered to be oversold (<=20).

revenue growth

year-on-year quarterly revenue growth grew by 3%, now sitting on 249.6m for the twelve trailing months.

more news about sqli.

2. novabase,sgps (nba.ls)

2.26% forward dividend yield and 14.03% return on equity

novabase s.g.p.s., s.a., through its subsidiaries, provides it consulting and services in portugal, europe, africa, the middle east, and internationally. it operates through two segments, next-gen and value portfolio. the next-gen segment develops it consulting and services to banks, insurance, capital markets, and telecommunication sectors. this segment operates under the celfocus brand name. the value portfolio segment operates and develops it consulting, staffing, and services under the neotalent brand. this segment involves in venture capital activities. novabase s.g.p.s., s.a. was incorporated in 1989 and is headquartered in lisbon, portugal.

earnings per share

as for profitability, novabase,sgps has a trailing twelve months eps of €0.25.

pe ratio

novabase,sgps has a trailing twelve months price to earnings ratio of 21.12. meaning, the purchaser of the share is investing €21.12 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.

more news about novabase,sgps.

3. coheris (coh.pa)

1.46% forward dividend yield and 21.37% return on equity

coheris sa provides customer relationship management (crm) and data analytics solutions in france and internationally. the company offers data solutions, such as digital and speech intelligence, cyber security, data science, data operating system, and data mining and machine learning services. it also provides crm customer care, sales force, and marketing automation services; and unified commerce, including digital in-store, wen-to-store, order management system, e-merchandising and searchandsing, store management, unified stocks, returns and refunds, and clienteling, as well as product recommendation and seller performance optimization services. in addition, the company offers e-merchandising and search software, as well as software merchandising services. it serves mutual insurance, bank and finance, agrifood, otc and pharmacy, luxury, retail, and public industries, as well as consumer goods industry and government. the company was incorporated in 1994 is based in suresnes, france. coheris sa is as subsidiary of chapsvision.

earnings per share

as for profitability, coheris has a trailing twelve months eps of €0.54.

pe ratio

coheris has a trailing twelve months price to earnings ratio of 7.81. meaning, the purchaser of the share is investing €7.81 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.37%.

yearly top and bottom value

coheris's stock is valued at €4.22 at 01:30 est, way under its 52-week high of €6.10 and way above its 52-week low of €2.40.

revenue growth

year-on-year quarterly revenue growth grew by 9.1%, now sitting on 14.46m for the twelve trailing months.

dividend yield

according to morningstar, inc., the next dividend payment is on jul 1, 2019, the estimated forward annual dividend rate is 0.03 and the estimated forward annual dividend yield is 1.46%.

more news about coheris.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com